Agendia has developed high-quality diagnostic methods using microarray gene expression profiling to determine the tumor's specific properties:
MammaPrint® can reliably predict whether an individual breast cancer patient is at high or low risk of disease recurrence. In addition, Agendia also offers services aimed at identifying the primary (original) tumor in patients diagnosed with distant metastasis (tumors that have spread from the original source to distant organs or lymph nodes).
Agendia's innovative and robust methods provide physicians and patients with crucial information for determining the optimal treatment plan based on personalized gene expression information.
Gene expression profiling is an important new tool in diagnosis, prognosis, and the identification of novel drug targets. Agendia strives to offer state of the art DNA microarray technology and analytical approaches to physicians and pharmaceutical companies, improving the accuracy of metastasis risk prediction, disease origin, targeted drug development or pre-selection of patients eligible for clinical trials.
It is Agendia's mission to provide cancer patients attainable access to the latest findings in gene-based diagnostics and thus improve the patient's quality of life by enabling effective personalized medicine.
